Cardiac transplantation is a highly successful treatment for end-stage heart failure, but its broader application is severely limited by donor organ availability and long-term complications.
Answers are grounded in this paper and cite their sources.
Urges alternatives to transplantation for end-stage HF; leaves open optimal strategies to expand donors and reduce complications.
Cardiac transplantation is currently a highly successful treatment for selected patients with end-stage cardiac failure. The long-term results are limited by the development of coronary artery vasculopathy, infection and malignancy. The activity of transplantation programmes worldwide is severely limited by the availability of donor organs. Further refinements of immunosuppressive agents are likely to result in improved prevention of both acute and chronic rejection. The donor pool is unlikely to be significantly extended as a result of measures to increase donor organ supply. Alternative methods to allograft transplantation need further investigation to increase the number of therapeutic options available for those patients with end-stage heart failure.
No takes yet. Share an insight, caveat, or question.
Mark Yeatman (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: